Valbiotis SAS (ALVAL) - Net Assets
Based on the latest financial reports, Valbiotis SAS (ALVAL) has net assets worth €6.96 Million EUR (≈ $8.14 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€14.39 Million ≈ $16.82 Million USD) and total liabilities (€7.43 Million ≈ $8.68 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check ALVAL tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €6.96 Million |
| % of Total Assets | 48.38% |
| Annual Growth Rate | 56.29% |
| 5-Year Change | -51.09% |
| 10-Year Change | 1786.45% |
| Growth Volatility | 791.1 |
Valbiotis SAS - Net Assets Trend (2015–2025)
This chart illustrates how Valbiotis SAS's net assets have evolved over time, based on quarterly financial data. See operational self-sufficiency of Valbiotis SAS to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Valbiotis SAS (2015–2025)
The table below shows the annual net assets of Valbiotis SAS from 2015 to 2025. For live valuation and market cap data, see Valbiotis SAS market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €6.96 Million ≈ $8.14 Million |
-32.86% |
| 2024-12-31 | €10.37 Million ≈ $12.12 Million |
-47.10% |
| 2023-12-31 | €19.60 Million ≈ $22.91 Million |
+47.22% |
| 2022-12-31 | €13.31 Million ≈ $15.56 Million |
-6.45% |
| 2021-12-31 | €14.23 Million ≈ $16.64 Million |
+101.20% |
| 2020-12-31 | €7.07 Million ≈ $8.27 Million |
-13.84% |
| 2019-12-31 | €8.21 Million ≈ $9.60 Million |
+10.80% |
| 2018-12-31 | €7.41 Million ≈ $8.66 Million |
-27.07% |
| 2017-12-31 | €10.16 Million ≈ $11.88 Million |
+2653.12% |
| 2016-12-31 | €369.00K ≈ $431.40K |
+361.25% |
| 2015-12-31 | €80.00K ≈ $93.53K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Valbiotis SAS's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 867800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €2.37 Million | 34.05% |
| Other Comprehensive Income | €7.85 Million | 112.71% |
| Other Components | €6.16 Million | 88.52% |
| Total Equity | €6.96 Million | 100.00% |
Valbiotis SAS Competitors by Market Cap
The table below lists competitors of Valbiotis SAS ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Higher Way Electronic Co Ltd
TWO:3268
|
$23.90 Million |
|
ECO WAVE POW.GL. SP.ADR/8
F:1KW0
|
$23.91 Million |
|
WITTED MEGACORP OYJ EO 1
F:8OS
|
$23.93 Million |
|
Eutilex.Co.Ltd
KQ:263050
|
$23.94 Million |
|
Mmcité a.s.
PR:MMCTE
|
$23.89 Million |
|
KPS Consortium Bhd
KLSE:9121
|
$23.88 Million |
|
Flagship Investments Ltd
AU:FSI
|
$23.88 Million |
|
Marti Otel Isletmeleri AS
IS:MARTI
|
$23.87 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Valbiotis SAS's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 10,368,000 to 6,961,000, a change of -3,407,000 (-32.9%).
- Net loss of 9,417,000 reduced equity.
- Share repurchases of 5,699,000 reduced equity.
- New share issuances of 5,699,000 increased equity.
- Other comprehensive income decreased equity by 9,714,000.
- Other factors increased equity by 15,724,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-9.42 Million | -135.28% |
| Share Repurchases | €5.70 Million | -81.87% |
| Share Issuances | €5.70 Million | +81.87% |
| Other Comprehensive Income | €-9.71 Million | -139.55% |
| Other Changes | €15.72 Million | +225.89% |
| Total Change | €- | -32.86% |
Book Value vs Market Value Analysis
This analysis compares Valbiotis SAS's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.94x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.13x to 2.94x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | €6.49 | €0.86 | x |
| 2016-12-31 | €0.10 | €0.86 | x |
| 2017-12-31 | €3.84 | €0.86 | x |
| 2018-12-31 | €1.97 | €0.86 | x |
| 2019-12-31 | €1.75 | €0.86 | x |
| 2020-12-31 | €0.96 | €0.86 | x |
| 2021-12-31 | €1.55 | €0.86 | x |
| 2022-12-31 | €1.32 | €0.86 | x |
| 2023-12-31 | €1.57 | €0.86 | x |
| 2024-12-31 | €0.66 | €0.86 | x |
| 2025-12-31 | €0.29 | €0.86 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Valbiotis SAS utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -135.28%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1040.55%
- • Asset Turnover: 0.06x
- • Equity Multiplier: 2.07x
- Recent ROE (-135.28%) is above the historical average (-157.39%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -935.44% | -7390.00% | 0.01x | 14.67x | €-746.90K |
| 2016 | -161.14% | -91.80% | 0.40x | 4.41x | €-629.80K |
| 2017 | -24.05% | -81433.33% | 0.00x | 1.25x | €-3.46 Million |
| 2018 | -67.04% | -6287.34% | 0.01x | 1.61x | €-5.71 Million |
| 2019 | -67.05% | -6048.35% | 0.01x | 1.83x | €-6.32 Million |
| 2020 | -53.54% | -123.84% | 0.15x | 2.94x | €-4.54 Million |
| 2021 | -61.00% | -2913.09% | 0.01x | 2.00x | €-10.10 Million |
| 2022 | -92.48% | -1568.41% | 0.03x | 2.04x | €-13.64 Million |
| 2023 | -37.59% | -155.67% | 0.14x | 1.70x | €-9.33 Million |
| 2024 | -96.69% | -5728.57% | 0.01x | 1.89x | €-11.06 Million |
| 2025 | -135.28% | -1040.55% | 0.06x | 2.07x | €-10.11 Million |
Industry Comparison
This section compares Valbiotis SAS's net assets metrics with peer companies in the Packaged Foods industry.
Industry Context
- Industry: Packaged Foods
- Average net assets among peers: $802,684,054
- Average return on equity (ROE) among peers: 6.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Valbiotis SAS (ALVAL) | €6.96 Million | -935.44% | 1.07x | $23.90 Million |
| Fleury Michon (ALFLE) | $136.16 Million | 10.87% | 2.05x | $109.11 Million |
| Sapmer (ALMER) | $34.85 Million | -17.39% | 3.84x | $29.26 Million |
| Paulic Meunerie Sa (ALPAU) | $1.59 Million | 10.03% | 3.96x | $6.83 Million |
| Poulaillon SA (ALPOU) | $26.79 Million | 15.63% | 1.97x | $31.94 Million |
| Rapid Nutrition PLC (ALRPD) | $22.00 Million | 8.66% | 0.27x | $3.95 Million |
| Danone SA (BN) | $4.51 Billion | 9.96% | 2.57x | $48.98 Billion |
| Bonduelle S.C.A. (BON) | $503.75 Million | 9.27% | 2.46x | $262.44 Million |
| Saint Jean Groupe Société anonyme (SABE) | $66.44K | 6.00% | 0.65x | $65.13 Million |
| Savencia SA (SAVE) | $1.99 Billion | 5.37% | 1.49x | $771.57 Million |
About Valbiotis SAS
Valbiotis SA engages in the research and development of dietary supplements to prevent metabolic and cardiovascular diseases in France and Asia. The company offers supplements for immunity and vitality, health and wellbeing, metabolic and cardiovascular health, and beauty and physical comfort. It also develops TOTUM-63 for the reduction of fasting blood glucose and treatment of type 2 diabetes; T… Read more